To examine intrafamily spread of respiratory syncytial virus infections and their associated illnesses, 36 families with 188 members were studied during an outbreak of such infections. Nurses visited every three to four days to obtain specimens for viral isolation and interview household members. The virus infected 44.4 per cent of families, and 21.9 per cent of all members. All age groups had appreciable attack rates (with a range of 16.8 per cent in adults to 29.4 per cent in infants). In infected families, 45.9 per cent of members became infected, including 10 of 16 infants. Secondary attack rate for all ages was 27 per cent, and that for infants 45.4 per cent. An infant's older sibling appeared most likely to introduce the virus into the family. Associated acute respiratory illnesses occurred in 94.9 per cent of cases, and appeared more severe than those not associated with respiratory syncytial virus. When the virus was introduced into a family the high attack rate produced an illness of age-related severity.
Summary Subchondral cystic lesions (SCLs) in the condyle of the third metacarpal bone (MCIII) were surgically treated in 15 horses. The median age at presentation was 18 months (range 10 months‐12 years) with 10 of 15 horses less than age 2 years. The SCLs were confined to the front limbs in all cases with 2 horses having bilateral lesions. Lesions were isolated to the medial condyle(s) of MCIII in 13 of 15 horses; a cystic lesion occurred in the lateral condyle in one horse and in the sagittal ridge in one horse. One horse with bilateral lesions had an additional cystic lesion located in the right medial femoral condyle. Fourteen of 15 horses had a history of moderate lameness attributable to the metacarpophalangeal joint; the lesion was an incidental finding in one horse. Duration of lameness ranged from 4 weeks to 8 months and was either acute in onset, or occurred intermittently and was associated with exercise. Fetlock flexion significantly exacerbated the lameness in all cases. Synovial effusion was absent in 8 (53%) cases. Cystic lesions were curetted arthroscopically in 12 horses, and through a dorsal pouch arthrotomy in 3 horses. Concurrent osteostixis of the cystic cavity was performed in 7 horses. Two horses were treated arthroscopically for osteochondral fragmentation of the proximodorsal aspect of the proximal phalanx one year following surgical curettage of the SCL. Twelve of 15 horses (80%) were sound for intended use following surgical treatment. Two horses did not regain soundness and follow‐up information was unavailable for one horse. Total period of follow‐up was 1–6 years. Follow‐up radiographic examinations were available for 9 horses. Mild periarticular osteophyte formation and enthesiophyte formation at the dorsal joint capsular attachments was present in 5 of the 9 horses. Bony ingrowth of the cystic lesion was detectable in 8 horses and enlargement of the cystic cavity was observed in one horse. Based on the information gained from this study, it would appear that surgical treatment of SCLs in the distal metacarpus can result in a favourable outcome for athletic use.
Summary Medical records and lifetime race results were obtained for 61 Standardbred racehorses treated consecutively from 1985 to 1992 with transection of the accessory ligament of the superficial digital flexor tendon (AL‐SDF) for tendinitis of one or both forelimbs. A clinical diagnosis of tendinitis was confirmed in all cases by ultrasonographic examination. After surgery, 50 (82%) horses raced and 42 (69%) completed 5 or more starts. Eight horses (13%) failed to start and/or complete 5 or more races due to a recurrence of tendinitis. Six (10%) horses did not start and/or complete 5 or more starts for reasons unrelated to tendinitis and 5 (8%) horses were lost to follow‐up. The median time between surgery and the first post operative start was 39 weeks. Fifty‐seven per cent of those horses to start after surgery completed 20 or more starts and 40% raced on 40 or more occasions. Of the 42 horses to complete 5 or more races, the median number of post operative starts was 37 at time of follow‐up. Thirty‐two of 50 (64%) horses to start after surgery established or lowered lifetime racemarks. Thirty‐six horses had raced prior to surgery. Thirty‐one of 36 (86%) horses returned to racing after treatment of SDF tendinitis with accessory desmotomy (AD) and 27 horses (75%) completed 5 or more starts. Median earnings per start decreased 25% after surgery. Twenty‐five horses had not raced prior to surgery. Nineteen (76%) horses in this group were age 2 years at time of injury. Nineteen of 25 (76%) horses started after surgery and 15 horses (60%) completed 5 or more starts. Horses that had not started prior to sustaining injury had significantly (P<0.05) less total earnings per horse and earnings per start after surgery than those horses that had previously raced. Horses that had started before surgery achieved significantly faster post operative lifetime racemarks than horses that had not raced before surgery. Horses that were age 2 years at time of injury did not differ statistically from horses older than 2 years in any post operative variable evaluated. There was no statistical difference in rate of recurrence of tendinitis between horses undergoing AD in one or both limbs for treatment of tendinitis occurring in one limb. This study suggests that transection of the AL‐SDF allows a high percentage of Standardbred horses with tendinitis to race and earn money without recurrence of tendinous injury. Horses that have not raced prior to tendinous injury may be expected to earn less money and achieve lower lifetime racemarks after surgery than horses that have raced prior to sustaining tendinous injury.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.